Werewolf Therapeutics and Ambros Therapeutics agreed to merge, with an oversubscribed $150 million private placement and a plan to advance neridronate toward a potential first FDA approval for complex regional pain syndrome type 1. The combined company will operate as Ambros Therapeutics and is expected to list on Nasdaq under ticker AMBX once the deal closes. The financing is expected to fund operations through topline data from the pivotal CRPS-RISE Phase III trial (NCT07210515), creating a runway aligned to a near-term clinical readout. Neridronate has already received Breakthrough Therapy, Fast Track, and Orphan Drug designations. The deal structure—using a public listing vehicle rather than a traditional IPO—is increasingly common for smaller biotechs seeking capital and market access without an initial public offering.